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Spermatocytic seminoma is a rare testicular neoplasm 
derived from mature germ cells (spermatogonia). This 
tumour was first distinguished from classical seminoma 
by Masson (Masson, 1946).  
This tumour occurs exclusively in the testes, in 




Classification of germ cell tumours (GCT) has not been 
adapted uniformly in the world. Two classifications 
most commonly used in the past were the modified 
WHO classification and the British Testicular Panel 
(BTTP) classification (Collins and Pugh, 1964). WHO 
has updated its classification in 2004 but spermatocytic 
seminoma remains classified together with other 
testicular GCT (Eble et al., 2004). In 1993, Grigor 
proposed a new classification based on biological 
features, and listed this tumour as a separate entity 
named spermatocytoma to distinguish it better from the 
classical seminoma (Grigor, 1993). In the Atlas of 
Tumor Pathology of Armed Forces Institute of 
Pathology (AFIP) a modified classification of testicular 
and paratesticular tumours and tumour-like lesions wa
suggested, where spermatocytic seminoma is also listed 
separately (Ulbright et al., 1999). More recently, a 
research team from the Erasmus University in 
Rotterdam proposed a new classification of GCT that
comprises entire body, in men and women, and 
classified spermatocytic seminoma as a separate type 
III GCT (Oosterhuis and Looijenga, 2005). 
Spermatocytic seminoma is classified in these five 
systems as follows: 
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An example of spermatocytic seminoma, HE-stained. 
 
Clinics and pathology 
Disease 
Spermatocytic seminoma (ICD-O code : 9063/3) 
Note 
Spermatocytic seminoma is a rare germ cell tumour 
(GCT) that occurs only in the testis of older men. 
Phenotype / cell stem origin 
The origin of spermatocytic seminoma from the germ 
cell lineage has been clearly demonstrated by a number 
of studies, however the stage of germ cell maturation 
from which the tumour originates has been a matter of 
debate (Eble, 1994; Rajpert-De Meyts et al., 2003; 
Looijenga et al., 2007; Waheeb and Hofmann, 2011). 
The initial hypothesis suggested that the spermatocyte 
was the progenitor cell (Masson, 1946 ; Rosai et al., 
1969). This hypothesis was supported by the 
subsequent studies of the Rotterdam group, which 
demonstrated in spermatocytic seminoma the 
expression of genes involved in the first step of meiosis 
(Looijenga et al., 2006; Looijenga et al., 2007). Other 
hypotheses, mainly based on comparative 
immunoprofiles, stipulated that spermatocytic 
seminoma might originate from type B spermatogonia 
(Romanenko and Persidskii, 1983; Rajpert-De Meyts et 
al., 2003). More recent studies support the origin from 
spermatogonia, both A and B, based on the discovery 
in the tumour of activating mutations in FGFR3 
(Goriely et al., 2009), a gene encoding a receptor which 
in the testis is expressed in spermatogonia (Juul et a ., 
2007; von Kopylow et al., 2010). Recently, a small 
subset of spermatocytic seminomas expressing OCT2 
and likely derived from A-dark spermatogonia (stem 
spermatogonia) was detected (Lim et al., 2011). 
The expression of some proteins linked to the iniation 
of meiosis in spermatocytic seminoma is explained by 
the marked plasticity of malignant germ cells, which 
are capable of partial maturation towards primary 
spermatocyte but are unable to truly enter or complete 
meiosis (Lim et al., 2011). 
Spermatocytic seminoma begins as intratubular clump 
of cells, which gradually spread inside seminiferous 
tubules and finally break into the interstitial 
compartment (Eble, 1994). 
Embryonic origin 
Spermatocytic seminoma is not of embryonic origin 
and is not derived from carcinoma in situ, the 
gonocyte-like intratubular precursor lesion for germ 
cell tumours of adolescents and young adults (Muller et 
al., 1987). 
Etiology 
Based on the presumed origin of spermatocytic 
seminoma from mature (postpubertal) germ cells, it has
been hypothesised that the increased proliferation of 
these cells causes the growth of the tumours, but the 
etiology has long been unknown. Molecular 
cytogenetic analysis postulated that an amplification of 
a locus on chromosome 9, with the DMRT1 locus as 
the candidate gene could be involved (Looijenga et l., 
2006).  
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A high power image showing characteristic polymorphism of the cell nucleus size of spermatocytic seminoma. 
 
Subsequently, a targeted molecular analysis of a series 
of spermatocytic seminomas for the presence of 
mutations in genes which had been previously linked to 
paternal-age-effect disorders, revealed activating 
mutations in FGFR3 or HRAS in about 25% of tumour 
specimens (Goriely et al., 2009). This finding 
suggested that random mutational events may occur in 
spermatogonia and accumulate with age, leading to a 
selective proliferation of cells with mutations that give 
them growth or survival advantage and eventually to 
tumour formation (Goriely and Wilkie, 2012). 
Epidemiology 
Spermatocytic seminoma is rare and represents less 
than 1% of primary germ cell tumours in the testis. In 
comparison to classical seminoma this tumour is about 
20-25 times less common (Eble, 1994). Reported age at 
diagnosis ranges from 19 to 92, with a median age of 
54 years (Carrière et al., 2007). 
Clinics 
Pure spermatocytic seminoma has a relatively mild 
clinical course. Most patients present with a painless 
swelling of one testis, but in some cases tenderness wa  
reported.  
Bilateral presence of spermatocytic seminoma is not 
uncommon (Looijenga et al., 2007). Metastases are 
very rare and have been reported nearly only in cases 
with sarcomatous transformation (see Evolution). 
Cytology 
A characteristic feature of spermatocytic seminoma is  
great variablity of the cell size, so the tumour cells are 
roughly divided into three types according to the  
nuclear size: large, intermediate and small (Masson, 
1946; Eble, 1994). Some nuclei may exhibit a presence 
of thread-like chromatin. 
Pathology 
In gross appearance spermatocytic seminomas consist 
of light greyish soft tissue, usually easily separable 
from the normal testis parenchyma but some tumours 
seem composed of smaller nodules. In rare instances, 
the pre-invasive intratubular spermatocytic seminoma 
can be detected (Eble, 1994). 
There is no specific immunocytological marker for 
spermatocytic seminoma.  
Genes/antigens that are highly expressed in 
spermatogonia (some of them also present either in 
primary spermatocytes or in gonocytes), are usually 
detected in spermatocytic seminoma.  
The so-called cancer-testis antigens are highly 
expressed in spermatocytic seminomas, both at the 
transcript and protein level: SSX1, SSX2, SSX3, SSX4 
(Stoop et al., 2001; Lim et al., 2011), MAGE-A4 
(Aubry et al., 2001), NY-ESO-1/CTAG1A (Satie et al., 
2002), GAGE4 (Looijenga et al., 2006), SAGE1 
(Looijenga et al., 2006; Lim et al., 2011).  
Other proteins were described mainly in the studies by 
Stoop et al. 2001, Rajpert-De Meyts et al. 2003, and
Looijenga et al. 2006; and include, among others: 
SYCP1, NSE (neuron-specific enolase), CHK2, VASA, 
DMRT1 (Looijenga et al., 2007), FGFR3 or HRAS 
(Goriely et al., 2009), (reviewed by Waheeb and 
Hofmann, 2011). Recently, a subset of spermatocytic 
seminomas that express OCT2, a marker of stem 
spermatogonia in the testis, was detected (Lim et al., 
2011). 
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A. MAGE-A4 antigen is abundant is spermatocytic seminoma (visible in a lower part of the picture). Note that MAGE-A4 is also present in 
normal spermatogonia (visible in the upper part) (from Rajpert-De Meyts et al., Histopathology, 2003). B. Immunohistochemical 
expression of FGFR3 in a sample of spermatocytic seminoma with a mutation in the FGFR3 gene (Goriely et al., 2009). C. 
Heterogeneous nuclear expression of the HRAS protein in a spermatocytic seminoma (Goriely et al., 2009). 
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Genes expressed in embryonic germ cells and 
gonocytes as well as in classical seminoma and 
embryonal carcinoma, but not in the normal adult tes is, 
e.g. OCT4, NANOG or PLAP (placental-like alkaline 
phosphatase), are usually undetectable in spermatocytic 
seminoma (Dekker et al., 1992; Kraggerud et al., 1999; 
Rajpert-De Meyts et al., 2003; Looijenga et al., 2007).  
Likewise, proteins highly abundant in post-meiotic 
spermatids, e.g. p19INK4d, are not present in 
spermatocytic seminoma.  
High expression of p53 protein in a subset of cells wa  
demonstrated in approximately 80% of cases. The 
expression of telomerase (the RNA component) in 
spermatocytic seminoma was found to be moderate: 
lower than in classical seminomas but higher than in 
mature teratomas (Delgado et al., 1999). 
In differential diagnosis, spermatocytic seminoma has 
to be distinguised from classical seminoma, pure 
embryonal carcinoma and testicular lymphoma (Eble, 
1994; Looijenga et al., 2007; Lim et al., 2011). 
Treatment 
Spermatocytic seminoma is treated by surgery 
(orchiectomy) alone followed by surveillance. The 
recurrence is extremely rare. 
Evolution 
Some cases of spermatocytic seminoma may undergo 
sarcomatous transformation and spread outside the 
testis (Floyd et al., 1988). 
Prognosis 
Sarcomatous differentiation is a very serious 
complication, often resulting in death (Eble, 1994). 
Genetics 
Note 
Very few genetic studies of spermatocytic seminomas 
have been performed, due to the rarity of this tumor.  
Only one consistent amplification in chromosome 9p 
was reported (Looijenga et al., 2006). More recent 
genetic study using parallel sequencing identified 
activating somatic mutations (in tumour DNA) in two 
genes, which are physiologically connected to each 
other; FGFR3 (1948A>G), detected in 2/26 samples, 
and HRAS (181C>A and 182A>G, QK650E), detected 
in 5/26 spermatocytic seminomas (Goriely et al., 2009). 
 These mutations - if occuring somatically - are 
oncogenic and have been linked to other cancers, e.g. 
bladder cancer.  
If these mutations are transmitted in germline - they 
cause severe, often lethal skeletal abnormalities, e.g. 
thanatophoric dysplasia or Costello syndrome.  
Milder ligand-dependent mutations in FGFR3 can 
cause achondroplasia.  
All FGFR3 and HRAS mutations identified in 
spermatocytic seminoma were homozygous and present 
in significantly older men than the average age of 
diagnosis, consistent with the paternal age-effect 
mutations (Goriely et al., 2009). 
Cytogenetics 
Note 
Cytogenetic studies demonstrated variable ploidy of the 
different cell populations in spermatocytic seminoma, 
with prevalence of diploid and polyploid cells, but no 
haploid values were found (Talerman et al., 1984; 
Muller et al., 1987; Dekker et al., 1992; Kraggerud et 
al., 1999). 
Cytogenetics Molecular 
The first molecular study of four spermatocytic 
seminomas by comparative genomic hybridisation 
(CGH) reported a gain of chromosome 9, and less 
consistent gains of chromosomes 1 and 20, and loss of 
chromosome 22 material (Rosenberg et al., 1998). The 
specific gain of chromosome 9, in one tumour 
restricted to a region in 9p, was subsequently 
confirmed by the same group, suggesting the 
involvement of DMRT1 (Looijenga et al., 2006). 
Genes involved and proteins 
DMRT1 (doublesex and mab-3 related 




A transcription factor involved in sex differentiation, 
germ cell maturation and meiosis regulation. 
Protein 
Contains a zinc finger-like DNA-binding motif (DM 
domain). 





A member of the FGF receptor family, can bind at lest 
20 different factors and numerous modulating co-
factors. 
Protein 
Receptor with tyrosine kinase activity. 
HRAS (v-Ha-ras Harvey rat sarcoma 




A classical proto-oncogene, involved in signal 
transduction of several pathways. 
Protein 
Can bind GTP/GDP or have GTPase activity. 
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